GlycosBio’s path toward becoming a leader in the production of biochemicals.”
GlycosBio’s commercial facility is being developed in several phases with a production rate capacity of up to 30,000 metric tons per year being reached by 2014 with a subsequent scale-up to 90,000 metric tons. Targeted biochemical for GlycosBio’s plant include isoprene, a key building block molecule used in the synthetic rubber market. GlycosBio will initially utilize the facility to validate the ability to produce industrial ethanol from crude glycerin. Global company has more than 50 years of experience in engineering and constructing facilities for clients across a wide range of industries around the world. GlycosBio a quality state-of-the-art facility always emphasizing health, safety, security and the environment. We envision this project will be delivered on time with optimum cost as we have successfully done in many of our previous projects and completed cost efficiently.”
“GlycosBio will play a significant role in strengthening our value chain for industrial bioprocess and biomanufacturing within the Bio-XCell ecosystem. Apart from human capital development and expanded investment opportunities, its technology will be a critical contributor to Malaysia’s near and long-term industrial and biotechnology goals,” said Ramli.
GlycosBio first announced its intention to expand to Malaysia in 2010 through its partnership with Bio-XCell and is the first US-based company to begin construction at the industrial park in Johor, Malaysia. GlycosBio is also working closely with BiotechCorp, the national agency set up by the Malaysian government for the development of biotechnology in Malaysia. GlycosBio also received BioNexus status in 2011, a recognition awarded by the Malaysian Government to qualified companies that participate in and undertake value-added biotechnology activities in Malaysia.
About Glycos Biotechnologies, Inc.
Glycos Biotechnologies, Inc. (GlycosBio) is an international biochemical company focused on the commercialization of advanced metabolic engineering and microbial strain development which when combined with the development of related engineering processes convert multiple, low-value feedstocks into a range of high value sustainable chemicals...We have coveted numerous recognition and awards as a result of maintaining an excellent safety record and successfully adherence to strict policies. Since year 2000, Toyo Malaysia has successfully completed all our projects without LTI.
Bio-XCell is a biotechnology park and ecosystem hub for industrial and healthcare biotechnology, with a focus on manufacturing and R&D. Developed by Malaysian Bio-XCell Sdn Bhd, a joint venture company between BiotechCorp and UEM Land, the park is slanted to be the new regional biotech hub of Asia. Capitalising on value propositions of both its shareholders, Bio-XCell provides comprehensive infrastructure, services, incentives and benefits to drive the growth for the biotechnology sector.
Strategically located in Nusajaya, Iskandar Malaysia, the resource-rich state of Johor, Bio-XCell provides global connectivity through the network of five seaports and two international airports, all within 59kms. For information or leasing inquiries, log on to http://www.bio-xcell.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebGlycosBioMalaysiaFacility/Toyo/prweb9032848.htm